<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621333</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH003</org_study_id>
    <nct_id>NCT02621333</nct_id>
  </id_info>
  <brief_title>Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma</brief_title>
  <official_title>Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Dayi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tangshan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>150th Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Nanyang Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Shangqiu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anyang Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puyang Oilfield General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenma Medical Group General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiaozuo Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 152th Central Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, open, multicenter phase Ⅱ study to evaluate the efficacy&#xD;
      of cytokine-induced killer cells combined chemotherapy in stage Ⅳ naive EGFR wild-type lung&#xD;
      adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is still no great improvement in advanced EGFR wild-type lung adenocarcinoma although&#xD;
      great progress was made in treatment of non-small cell lung cancer. It's necessary to explore&#xD;
      the treatment mode of this kind of patients. As the progress was made in tumor immunity and&#xD;
      immunotherapy, more and more cancer therapists accept the treatment model of chemotherapy&#xD;
      combined immunotherapy. And now chemotherapy combined autologous CIK cells is one kind of&#xD;
      common treatment model in some countries. Investigators try to evaluate the efficacy and&#xD;
      safety of this kind of treatment model in patients with stage Ⅳ naive EGFR wild-type lung&#xD;
      adenocarcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    As there are so many clinical trials in progress and the number of patients enrolled limited.&#xD;
  </why_stopped>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival time</measure>
    <time_frame>from the day of randomization to the day of death, up to 36 months</time_frame>
    <description>overall survival time aims at from date of randomization until the date of death from any cause, up to 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>from the day of randomization to the day of first detecting progression, up to 24 months</time_frame>
    <description>time to progression points to from date of randomization until the date of first documented progression, up to 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>one year</time_frame>
    <description>the partion of overall remission in total proportion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>CIK combined chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous CIK combined chemotherapy group Drugs: platinum combined doublets; After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-indued killer cells are transfused into the vein of patients in one hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>platinum combined doublets Drugs: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/ m2，D1-3 or carboplatin AUC=5, D1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK</intervention_name>
    <description>platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.</description>
    <arm_group_label>CIK combined chemotherapy group</arm_group_label>
    <other_name>autologous cytokine-induced killer cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.</description>
    <arm_group_label>CIK combined chemotherapy group</arm_group_label>
    <arm_group_label>chemotherapy group</arm_group_label>
    <other_name>platinum combined doublets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed as stage Ⅳ naive EGFR wild-type lung adenocarcinoma by image, tissue and/or&#xD;
             cytology; or relapse after operation (if the patient received adjuvant chemotherapy&#xD;
             and the interval between the last chemotherapy and relapse is at least six months. The&#xD;
             detection method of EGFR mutation is ARMS.&#xD;
&#xD;
          2. EML4-ALK fuse gene is negative and the detection of EML4-ALK is FISH or ventana IHC.&#xD;
&#xD;
          3. There should be at least one measurable lesions (by CT or MRI)&#xD;
&#xD;
          4. No other cancer history ( except skin squamous cell carcinoma after surgery)&#xD;
&#xD;
          5. Age between 18 and 75 years old&#xD;
&#xD;
          6. World health organization- Eastern Cooperative Oncology Group Performance Status 0-1&#xD;
&#xD;
          7. Life expectancy more than 3 months and can be followed-up&#xD;
&#xD;
          8. Patients must have adequate organ and marrow functions as defined below: white blood&#xD;
             cells: more than 3.5×109/L, Neutrophils: more than 1.5×109/L, Platelets: more than&#xD;
             80×109/L, Hemoglobin more than 90g/L, Serum total bilirubin less than 1.5 folds of the&#xD;
             upper normal limit (ULN), Serum glutamic-oxal&#xD;
&#xD;
             (o) acetic transaminase: less than 2.5×ULN (if there is liver metastasis less than&#xD;
             5×ULN); Serum creatinine: less than 1.0×ULN, Prothrombin time, Active partial&#xD;
             thromboplastin time, Fibrinogen, Thrombin time are in normal ranges.&#xD;
&#xD;
          9. Women of child-bearing period must take effective contraceptive measures during all&#xD;
             the time of study. During the period of study the results of blood and urine pregnancy&#xD;
             test should be negative.&#xD;
&#xD;
         10. Men should take effective contraceptive measures from the beginning of therapy to one&#xD;
             month after the last cycle of chemotherapy.&#xD;
&#xD;
         11. Willing to comply with the ban and constraints for this study protocol specified.&#xD;
&#xD;
         12. Informed consent and willing to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Accepted other study drugs 30 days before the beginning of this study.&#xD;
&#xD;
          2. Brain metastases with clinical symptoms ( with exception of being controlled after&#xD;
             radiation)&#xD;
&#xD;
          3. Active viral or bacterial infection and can't be controlled with appropriate&#xD;
             anti-infection treatment&#xD;
&#xD;
          4. Known as HIV infection, syphilis serology reaction positive, active hepatitis B virus&#xD;
             or hepatitis C virus infection&#xD;
&#xD;
          5. Suffering from mental illness or other illness, such as heart or lung disease,&#xD;
             diabetes, etc. that can not be controlled, and can not be coped with study treatment&#xD;
             and monitoring requirements.&#xD;
&#xD;
          6. Known allergy to any kind of component of study drugs&#xD;
&#xD;
          7. Active rheumatic diseases&#xD;
&#xD;
          8. Organ transplant recipients&#xD;
&#xD;
          9. Poor compliance&#xD;
&#xD;
         10. Pregnant women&#xD;
&#xD;
         11. Lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quanli Gao, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university</name>
      <address>
        <city>ZhengZhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X, Li H. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012 Nov;61(11):2125-33. doi: 10.1007/s00262-012-1260-2. Epub 2012 May 13.</citation>
    <PMID>22581306</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011 Oct;60(10):1497-502. doi: 10.1007/s00262-011-1060-0. Epub 2011 Jun 17.</citation>
    <PMID>21681372</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang S, Wang Z. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer. Int Immunopharmacol. 2015 Sep;28(1):22-8. doi: 10.1016/j.intimp.2015.05.021. Epub 2015 May 23. Review.</citation>
    <PMID>26013109</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Quanli Gao</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>terminated as the slow enrollment</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

